Datamedsai

Website

Datamedsai DataMEDS AI is a healthcare technology and pharmaceutical logistics company. Our solutions provide a seamless prescription ecosystem through an inte

We simplify the logistics of prescription fulfillment from the manufacturer and provider to the patient.

DataMEDS AI is expanding its ecosystem and advancing its proprietary technologies through an amended and restated letter...
10/22/2026

DataMEDS AI is expanding its ecosystem and advancing its proprietary technologies through an amended and restated letter of intent with Datavaultai and other strategic partners.

The initiative follows recent FDA guidance on prescription drug applications and software, establishing a roadmap to further optimize the HealthLivesHere mobile application.

Through planned integrations with Datavault AI, Data Health Partners, EOS Technology Holdings, Scilex, and HealthBridge Advisors, DataMEDS aims to advance its EinsteinRx™ AI and PharmacyChain™ platforms, supporting secure, autonomous drone medication delivery, biometric verification, and enhanced health outcome tracking. $MEDS Blockchain HealthcareInnovation

Read the full press release for more: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-enters-into-amended-and-restated-loi-to-license-and-acqui-1239896

DataMEDS SI proudly applauds the U.S. FDA’s proposed “Interim Access Policy for Compounding Using Certain Peptides.” Wit...
10/16/2026

DataMEDS SI proudly applauds the U.S. FDA’s proposed “Interim Access Policy for Compounding Using Certain Peptides.” With the U.S. compounding pharmacy market projected by Precedence Research to surge from $18 billion in 2025 to over $34 billion annually by 2035, this regulatory evolution opens critical pathways to expand safe, compliant patient access.

$MEDS is fully positioned to capitalize on this regulatory milestone through Corexa’s three divisions, leveraging Corexa Pharmacy to fill compliant peptide prescriptions, Corexa Distribution to supply independent pharmacies nationwide from our Florida facility, and Corexa Tech & Hub to scale physician connectivity and prescription routing via the HealthLivesHere application.

Read the full press release for more: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-applauds-fdas-proposed-interim-access-policy-for-compounding-1237535

DataMEDS SI is proud to share that our subsidiary, Helomics Corporation, has announced a major coverage policy update: H...
10/12/2026

DataMEDS SI is proud to share that our subsidiary, Helomics Corporation, has announced a major coverage policy update: Humana Medicaid has added the ChemoFx® Assay for gynecologic cancers to its coverage policy.

This policy, effective July 22, 2026, helps provide broader access for qualifying patients, including those undergoing initial biopsy or surgery, facing rare or treatment-refractory cancers, or navigating recurrent conditions.

By evaluating how a patient’s live tumor cells respond to various chemotherapy options, ChemoFx gives oncologists critical, data-driven insights to help inform personalized treatment choices.

With prior investments in our Pittsburgh-based, CLIA-certified laboratory’s automation, we are fully prepared to support scaled testing volumes as adoption expands. $MEDS

Read our full press release for complete details and disclosures: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-si-announces-helomics-receives-medicaid-coverage-policy-for-1235643

10/01/2026

Interim Co-CEO Gerald Commissiong joined Scripps News this morning to discuss how AI is increasing healthcare costs and the Trump Administration’s decision to issue $500 refunds to select enrollees in Affordable Care Act plans. $MEDS

Today, DataMEDS AI announced that Corexa Pharmacy, a division of Corexa, recorded a preliminary $1 million in unaudited ...
10/01/2026

Today, DataMEDS AI announced that Corexa Pharmacy, a division of Corexa, recorded a preliminary $1 million in unaudited revenue for September 2026 - a 66 percent increase from July of this year. 

This growth is fueled by the recent launch of TolloHealth’s proprietary dietary supplements and medical foods combined with strong organic expansion of our retail customer base. 

Interim Co-CEO Gerald Commissiong noted “Corexa Pharmacy will be showcased as a model for other pharmacies within Corexa Health’s over 6,500 independent pharmacy network, comprised of physical retail locations that are seeking to expand into patient service centers to better help manage the large population of GLP-1 receptor agonist consumers and Long COVID patients.”

Read the full press release to learn more: https://datamedsai.com/datameds-ais-corexa-pharmacy-surpasses-1-million-in-monthly-revenue/

09/29/2026

Appearing on NewsNation this morning to discuss the possiblity of AI driving a rise in healthcare costs, DataMEDS AI Interim Co-CEO Gerald Commissiong broke down what’s really happening: we are witnessing an "AI war" in healthcare, where systems are optimized for billing and delayed service rather than healing. The fundamental flaw in our current model is that the system rewards coding, not outcomes.

At DataMEDS, we believe healthcare shouldn't look like a menu of fragmented charges. Through our Health Lives Here app, we are shifting the paradigm toward total cost of care and outcomes-based practice. Patients deserve to be diagnosed faster, get better faster, and experience a total package of wellness rather than getting bogged down by automated coding obstacles. $MEDS

DataMeds AI and Tollo Health are proud to announce the official launch of the Health Lives Here mobile app, initially fo...
09/28/2026

DataMeds AI and Tollo Health are proud to announce the official launch of the Health Lives Here mobile app, initially focused on supporting users of GLP-1 receptor agonist medications, with marketing being driven through our partnership with NFL Alumni Health.

Powered by our advanced AI platform EinsteinRx™ and smart contracts platform PharmacyChain™, the app unifies telemedicine access, direct-to-home pharmacy delivery through Corexa Health, wearable data integration, and an AI health coach to simplify the patient journey. We plan to expand our target populations in Q4 2026 to include patients managing Long COVID, followed by cancer care.

This launch marks a major milestone in our mission to vertically integrate Health IT, telemedicine, and pharmacy infrastructure to deliver smarter, more connected care. $MEDS

Read the full press release here to learn more: https://hubs.la/Q04yrv5b0

We are thrilled to announce that DataMeds AI will be presenting at the 2026 National Telehealth and Virtual Care Summit ...
09/25/2026

We are thrilled to announce that DataMeds AI will be presenting at the 2026 National Telehealth and Virtual Care Summit next week!

As the healthcare landscape rapidly evolves, Interim Co-CEO, Gerald Commissiong, will take the stage to share how DataMeds AI is pioneering a new standard for connected care.

We look forward to connecting with fellow healthcare leaders, clinicians, and innovators in Las Vegas to discuss how cutting-edge technology and patient-centric design can expand care access for communities that need it most. $MEDS

Read the full press release here: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-to-present-at-2026-national-telehealth-and-virtual-care-s-1227063

DataMEDS AI’s digital evolution is officially complete with the launch of our newly redesigned corporate website: http:/...
09/21/2026

DataMEDS AI’s digital evolution is officially complete with the launch of our newly redesigned corporate website: http://www.DataMEDSAI.com 💻

This revamp reflects a major milestone for our company, aligning our brand identity with our new strategic marketing initiatives following the recent acquisition of the Helomics Diagnostics Lab.

We invite our partners, shareholders, and the broader community to explore our new digital home and learn more about how we are transforming the healthcare experience. $MEDS

DataMEDS AI is expanding its reach into oncology with the acquisition of Axe Compute’s Helomics AI cancer diagnostics la...
09/15/2026

DataMEDS AI is expanding its reach into oncology with the acquisition of Axe Compute’s Helomics AI cancer diagnostics laboratory business.

This strategic, stock-for-assets transaction thrusts DataMeds AI directly into the $40 billion U.S. cancer diagnostic and treatment solutions market. By integrating Helomics’ CLIA/CAP-certified clinical laboratory and pioneering AI precision-medicine platform into our ecosystem, we are expanding our ‘Health Lives Here’ application beyond GLP-1 side effects and Long COVID to spearhead advanced cancer screening, molecular profiling, and treatment solutions, especially in underserved rural areas. $MEDS

Read our full press release for complete details and disclosures: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai.-acquires-helomics-ai-cancer-diagnostics-lab-and-precisio-1221352

Address

Tampa, FL

Website

Alerts

Be the first to know and let us send you an email when Datamedsai posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category